drugset / Trial / NCT04406870

Sirolimus in the Treatment for Infantile Hepatic Hemangioendothelioma(IEEH)

NCT04406870

Phase 4 Unknown 36 enrolled Shanghai Children's Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Infantile hepatic hemangioendothelioma (IHHE) is an infantile hemangioma involving the liver.Since 2008, propranolol has been used for the treatment of hemangioma, and some researchers have also started to report the use of propranolol for the treatment of infantile hepatic hemangioma in children. Sirolimus can be used in patients with vascular malformations such as hemangiomas. IHHE is also an infantile hemangioma involving the liver,thus sirolimus may paly the role in treatment of IHHE.The clinical trial explores the efficacy of sequential treatment of sirolimus to refractory IHHE patients resistant with propranolol, to improve the therapeutic effect, reduce the side effects of traditional treatment methods (hormones, interferon), and reduce the number of operations and interventions and to provide a clinical basis for the application of the new therapeutics model of IHHE of "propranolol + sequential sirolimus treatment".

Timeline

Start
2020-07
Primary completion
2024-06-30
Completion
2025-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 0.8 mg/m2 Oral
Background Propranolol Small molecule 1 mg/kg

Indications